50 g UTHEVER® NMN as 400 lozenges for convenient dosing
Shipping calculated at checkout
Lieferzeit: 3-4 Tage
AFEGA® UTHEVER® NMN provides 125 mg per lozenge in a container of 400 tablets and is intended for anyone who wants a convenient, flexible way to include NMN in their routine without powder or capsules that need to be opened. The tablets are intended for oral use and can be sucked, or chewed and then allowed to dissolve under the tongue.
NMN is one of the best-known NAD+ precursors and is mainly discussed in connection with cellular energy metabolism and healthy aging. The lozenge format is particularly suitable for people who want to divide their daily amount flexibly and use it conveniently while on the go.
Product format
- 400 lozenges with 125 mg NMN each
- Total amount: 50 g NMN
- Purity: > 99 %
- CAS: 1094-61-7
What makes this format practical
Each tablet contains 125 mg NMN. This makes it easy to divide the daily amount into different doses. For example, those who want to start with 250 mg daily take 2 tablets. It is also possible to distribute several smaller individual doses throughout the day.
Application
The tablets can be sucked or chewed and allowed to dissolve under the tongue. People who want to minimise how long the taste remains in the mouth may find the second method more practical.
What UTHEVER® means here
UTHEVER® stands for a clearly defined raw material brand. This product is therefore particularly suitable for users who value both NMN itself and a consistent branded raw material source.
Dosage
For information on dosage, please see the related blog post by Dr. Peter Niehenke.
Ingredients
125 mg NMN per tablet, together with the excipients needed for structural stability, consistent dosing and the intended dosage form:
- Piperitol – natural flavoring with a mild menthol character
- Magnesium stearate – plant-based anti-caking agent
- Silicon dioxide – inert excipient
- Isomalt – tooth-friendly sugar substitute
Further information
More detailed information about NMN and other substances can be found on the AFEGA Research Group operated Facebook page.
